• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Rimidi Partners with Quest Health to Improve Blood Glucose for Diabetes Patients via RPM

by Jasmine Pennic 06/18/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Rimidi Partners with Quest Health to Improve Blood Glucose for Diabetes Patients via RPM

What You Should Know: 

– Quest Health Solutions, a national leader in diabetes care, today announced compelling results from its Remote Patient Monitoring (RPM) program, developed in partnership with the digital health company Rimidi. In just two months, the Quest Health RPM Services—powered by Rimidi’s EHR-integrated platform—led to an 11% improvement in average blood glucose readings among participating patients.

– The collaboration highlights the power of combining direct-to-patient services with advanced technology to streamline clinical workflows and drive better health outcomes in chronic condition management.

Clinical Improvements in Early Results

The partnership has already demonstrated significant clinical impact. In an early cohort of patients using connected Blood Glucose Monitors, the program achieved measurable improvements in glycemic control:

  • Overall average glucose levels dropped by 11%, from 176 mg/dL to 157.5 mg/dL.
  • Morning glucose readings (between 5 a.m. and 9 a.m.) saw an even more significant drop of 16%, from 176 mg/dL to 147.9 mg/dL.
  • These improvements translated to an estimated A1C reduction of approximately 1% for morning readings and 0.7% for overall daily readings.

A key factor in the program’s success is the seamless integration of Rimidi’s platform into Quest’s athenahealth EHR system. This allows clinical staff to efficiently monitor and manage patients using both cellular-enabled Blood Glucose Monitors and Continuous Glucose Monitors (CGMs). The platform enables risk stratification, customizable alerts, and robust documentation tools that support both clinical decision-making and billing, making the entire RPM process more efficient.

“Rimidi makes RPM effortless. Our team and partners love the quick access to charting, billing, and patient info — all in one user-friendly platform,” said Jim Klauder, RD, CDCES, LDN, Head of Patient Care at Quest Health RPM Services.

RPM Offering Expansion Plans

Quest Health plans to expand its RPM offerings to include support for patients using additional devices, such as blood pressure monitors and pulse oximeters, and to offer its RPM services to healthcare providers across the country.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |